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lence of CA remaining relatively stable in recent decades. 
The 2 European projects, EUROCAT and EUROPLAN, have 
joined efforts to provide the first science-based and compre-
hensive set of recommendations for the primary prevention 
of CA in the European Union. The resulting EUROCAT-EURO-
PLAN ‘Recommendations on Policies to Be Considered for 
the Primary Prevention of Congenital Anomalies in National 
Plans and Strategies on Rare Diseases’ were issued in 2012 
and endorsed by EUCERD (European Union Committee of 
Experts on Rare Diseases) in 2013. The recommendations ex-
ploit interdisciplinary expertise encompassing drugs, diet, 
lifestyles, maternal health status, and the environment. The 
recommendations include evidence-based actions aimed at 
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 Abstract 
 Congenital anomalies (CA) are the paradigm example of rare 
diseases liable to primary prevention actions due to the mul-
tifactorial etiology of many of them, involving a number of 
environmental factors together with genetic predisposi-
tions. Yet despite the preventive potential, lack of attention 
to an integrated preventive strategy has led to the preva-
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reducing risk factors and at increasing protective factors and 
behaviors at both individual and population level. Moreover, 
consideration is given to topics specifically related to CA (e.g. 
folate status, teratogens) as well as of broad public health 
impact (e.g. obesity, smoking) which call for specific atten-
tion to their relevance in the pre- and periconceptional pe-
riod. The recommendations, reported entirely in this paper, 
are a comprehensive tool to implement primary prevention 
into national policies on rare diseases in Europe. 
 © 2014 S. Karger AG, Basel 
 Rare diseases include those disorders that affect a 
small fraction of the population, < 5 in 10,000 people ac-
cording to the European Union definition  [1] . Due to low 
prevalence, the vast majority of congenital anomalies 
(CA) have to be considered as rare diseases  [2] . Whereas 
the majority of rare diseases are of genetic origin, most 
CA have a multifactorial etiology, with a number of en-
vironmental factors (often different for specific birth de-
fects) triggering, in relation to specific genetic predispo-
sitions which are discovered recently with newest ge-
nomic technologies. Thus, the aetiopathogenesis of most 
CA involves a number of factors related to the parental 
living environment such as diet, lifestyle, or workplace, 
as well as maternal diseases and therapeutic treatments. 
Accordingly, CA are the paradigm example of rare dis-
eases liable to be reduced by well-targeted primary pre-
vention actions. Clinical, epidemiological, as well as ex-
perimental studies are providing a growing amount of 
information about recognized or potential risk factors 
for either individual or groups of CA. Nevertheless, little 
effort has been made till now to integrate such informa-
tion into science-based, comprehensive, and consistent 
policies.
 Effective protection of women and men during their 
fertile years and the fetus from teratogenic or mutagenic 
risk factors should be a priority public health target. Pri-
mary prevention actions can benefit the general popula-
tion as well as afford a specific protection to the fetus at a 
particularly vulnerable life stage; they can also benefit a 
fraction of genetically vulnerable individuals. To build up 
a science-based and comprehensive approach, interdisci-
plinary expertise is required, encompassing drugs, diet, 
lifestyles, maternal health status, and the environment.
 Rare diseases raise concern as an emerging public 
health issue. In 2008 the European Commission adopted 
the ‘Communication on Rare Diseases: Europe’s Chal-
lenges’ proposing an overall strategy to support Member 
States  [3] . In 2009 the European Council followed this by 
adopting the ‘Council Recommendation on an Action in 
the Field of Rare Diseases’ which recommends that Mem-
ber States establish and implement national plans or 
strategies for rare diseases or explore suitable measures 
for rare diseases in other public health strategies  [4] . Since 
the main core of rare diseases (approx. 80%) are genetic 
conditions, recommendations tackle approaches to guar-
antee early and accurate diagnosis and effective and af-
fordable treatment. However, primary prevention is in-
creasingly recognized as a relevant issue as well, in par-
ticular for CA. The specific aspects of CA as rare diseases 
have been thoroughly discussed in a EUROCAT (Euro-
pean Surveillance of CA) report published in 2012  [2] .
 EUROCAT is a European network of population-
based registries for the epidemiologic surveillance of CA. 
EUROCAT started in 1979 and currently surveys more 
than 1.7 million births per year, gathering data from 43 
high-quality multiple source registries in 23 countries 
and covering 29% of the European Union birth popula-
tion  [5] . EUROCAT has more recently been funded by 
the EU Public Health Programme as a Joint Action (2011–
2013) which includes a dedicated workpackage (Work-
package 7) on primary prevention. It is notable that in the 
35 years since EUROCAT started in 1979, the total prev-
alence of major CA has not fallen, mainly indicating a lack 
of effective new interventions in primary prevention de-
spite growing scientific knowledge.
 EUROPLAN (European Project for Rare Diseases Na-
tional Plans Development) has elaborated agreed tools 
for the development and implementation of national 
plans or strategies following the European Council Rec-
ommendations; in its second phase (2012–15), the project 
establishes an international and interactive network of 
policy makers and other stakeholders to speed up the im-
plementation of national plans/strategies for rare diseases 
through scientific and technical assistance  [6] . Within the 
frame of national plans/strategies for rare diseases, EU-
ROPLAN has considered primary prevention as a prior-
ity target, with specific attention towards CA. Thus, EU-
ROPLAN has joined efforts with EUROCAT in order to 
provide the first comprehensive set of recommendations 
for the primary prevention of CA in the European Union.
 The resulting ‘Recommendations on Policies to Be 
Considered for the Primary Prevention of Congenital 
Anomalies in National Plans and Strategies on Rare Dis-
eases’ were issued jointly by EUROCAT and EUROPLAN 
in 2012 and were endorsed by EUCERD (European 
Union Committee of Experts on Rare Diseases) in 2013 
 [7] . EUCERD is charged with aiding the European Com-
mission with the preparation and implementation of 
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community activities in the field of rare diseases, in coop-
eration and consultation with the specialized bodies in 
Member States and the relevant European authorities in 
the fields of research and public health action. The rec-
ommendations point out areas in which public health 
policies are needed, whereas specific policies should be 
developed by Member States on the basis of national pri-
orities and scenarios. As well as translating current evi-
dence to effective interventions at the individual and pop-
ulation level, Member States need a targeted research pol-
icy. Research on the causes of CA has suffered from a 
similar fragmented approach as preventive actions, and 
there remains much scientific uncertainty relating to en-
vironmental causes that can and should be resolved.
 In the context of these primary prevention recommen-
dations, ‘environmental’ is used in its broadest sense as 
non-genetic (although interacting with genetic factors), 
encompassing physical, chemical, biological, and social 
factors and concentrating on factors which are potential-
ly modifiable: this broad definition follows that of the
US National Institute of Environmental Health Sciences 
 [8–11] . 
 The recommendations are entirely reported here in 
their original format and are a ‘first step’. The next steps 
envisaged are to monitor their implementation in Nation-
al Rare Disease Plans and by doing so to share experience 
regarding specific policy actions, to evaluate the impact of 
policy actions through continuing surveillance of CA by 
EUROCAT, and to periodically update the scientific evi-
dence underpinning the recommendations as well as 
grow the evidence base regarding effective interventions.
 How the Recommendations Were Formulated 
 The recommendations have been developed and 
shared through a multistep process.
 A preliminary phase covered collection and analysis of 
relevant literature (peer-reviewed papers, reports from 
authorities from EU, EU Member States, and outside the 
EU) to define the main evidence-supported risk factors 
for CA.
 Seven working groups were then established among 
EUROCAT and EUROPLAN partners in order to iden-
tify public health actions for the primary prevention of 
CA at several levels (regulatory, monitoring, pre- and 
periconceptional care). Namely, the following issues were 
considered: medicinal drugs, folic acid and other nutri-
tion aspects, food safety, maternal lifestyles, maternal 
health and healthcare including chronic and infectious 
conditions, genetic factors and genetic counseling, and 
environment-related risk factors including the work-
place. Working group participants were identified on the 
basis of specific expertise and declaration of interest.
 In parallel, EUROPLAN performed a survey to collect 
the existing health policies, initiatives, and best practices 
regarding the primary prevention of CA from a selected 
panel of national experts from EU Member States. This 
step facilitated the exploitation of the added value from 
multidisciplinary expertise as well as the sharing of na-
tional experiences; moreover, this step provided support 
to a consensus approach for including the primary pre-
vention of CA in national plans on rare diseases.
 A consensus draft of the recommendations was pre-
pared by the working groups in April 2012. This first draft 
was discussed in several joint sessions to be validated 
from both standpoints of scientific evidence and applica-
bility. An advanced draft was then presented during a 
specific session at the EUROCAT Registry Leader Meet-
ing (Budapest, June 13–15, 2012). The draft was revised 
taking into account the input of EUROCAT Registry 
Leaders and the comments of EUROCAT Project Man-
agement Committee (Ingeborg Barisic, Elisa Calzolari, 
Rhonda Curran, Helen Dolk, Ester Garne, Lorentz Ir-
gens, Babak Khoshnood, Domenica Taruscio, Diana 
Wellesley) in June 2012. Upon approval by the EURO-
CAT Steering Committee (December 2012), the docu-
ment was sent to the policy officer at the Directorate of 
Public Health at the European Commission in Luxem-
bourg (Dr. Antoni Montserrat) and was finally endorsed 
by EUCERD in 2013.
 Recommendations on Policies to Be Considered for 
the Primary Prevention of CA in National Plans and 
Strategies on Rare Diseases 
 Most CA are rare and form an important group of rare 
diseases for which EU Member States are developing na-
tional plans. The primary prevention of CA was identified 
as an important action in the field of rare diseases in the 
communication from the Commission to the European 
Parliament, the Council, the European Economic and So-
cial Committee, and the Committee of the Regions of No-
vember 11, 2008. However, it has not been included in the 
Council Recommendation on an action in the field of rare 
diseases of June 8, 2009. This document aims at providing 
an outline of evidence-based policy actions for the pri-
mary prevention of CA. It does not seek to recommend 
specific policy options but rather to indicate the areas that 
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Member States could target in their strategies for the pri-
mary prevention of CA. EUROPLAN  [6] will support and 
facilitate Member States to incorporate the recommenda-
tions specified here in their national plans and will facili-
tate exchange of experience among Member States in col-
laboration with EUROCAT  [5] .
 The causes of CA can be environmental, genetic, or an 
interaction involving both genes and environment  [8–
11] . Within the scope of this document, primary preven-
tion includes any evidence-based action aimed at reduc-
ing environmental risk factors for CA and increasing pro-
tective environmental factors. Such factors act in the 
periconceptional period most often before the pregnancy 
has been confirmed. Whereas actions based on the pre-
cautionary principle fall mainly outside the scope of this 
document, in some cases precautionary actions have been 
quoted when they may bear significant public health and/
or social benefits. Primary prevention also includes pre-
conceptional counseling concerning genetic risks but 
does not include preimplantation diagnosis. The primary 
prevention of CA includes factors that are common to 
other diseases as well as factors specific to CA. Policies 
aimed at promoting safer foods and environment, healthy 
dietary habits and lifestyles, as well as reducing the health 
impact of chronic diseases are expected to reduce the 
prevalence of CA as well as many other diseases. How-
ever, elaboration of these policies needs to pay special at-
tention to their relevance in the pre- and periconception-
al period. Rather than pinpointing specific actions, which 
may have a limited impact in isolation, it is advisable that 
Member States would integrate the different recommen-
dations within a strategy for primary prevention.
 The Scope of Policy Actions Needed for the Primary 
Prevention of CA 
 In the Field of Medicinal Drugs 
•  To advise women taking medication to seek medical 
advice before trying to get pregnant  [12] ;
 •  to ensure that guidelines are, or are going to be, made 
available for physicians regarding risk-benefit balance for 
use of medications in pregnancy, particularly those med-
ications used for treating chronic diseases  [13–17] ;
 •  to provide a teratogen information service where 
specialized advice can be sought by women and profes-
sionals  [18] ;
 •  to conduct postmarketing pharmacovigilance to de-
tect any risk of CA associated with the use of medications 
with the support of population-based CA registries  [19] .
 Notes 
 Medications of particular concern include antiepilep-
tics, folate antimetabolites, antiblastic agents, warfarin 
and related anticoagulants, retinoic acid derivatives, 
ACE-inhibitors, and AT1 receptor antagonists  [13] . 
However, information on the human teratogenicity of 
most medications is limited  [14, 15] .
 There is extensive literature investigating the relative 
teratogenicity of different antiepileptic medications  [16] . 
For antiasthmatics and antidepressants, national guide-
lines need to take into account the growing evidence base 
 [17] .
 In the Field of Food/Nutrition and Lifestyle 
•  To improve folate status through periconceptional 
supplementation with folic acid, promotion of the con-
sumption of foods rich in natural folates, and the appro-
priate use of fortified foods  [20–23] ;
 •  to prevent overweight/obesity and underweight  [24–
26] ;
 •  to promote effective information on diet and nutri-
tion in women at childbearing age, minimizing the risks 
of deficiency and/or overdosing of vitamins and essential 
trace elements  [27–31] ;
 •  to further the implementation of EU food safety 
strategies to prevent food contamination by recognized 
developmental toxicants  [32–35] ;
 •  to reduce active and passive smoking  [36, 37] ;
 •  to promote alcohol avoidance in women who are 
pregnant or wishing to get pregnant  [38–41] ;
 •  to pay special attention to diet and lifestyles in com-
munities with low socio-economic status or of recent im-
migrants.
 Notes 
 Strong scientific evidence showed that folate-rich diets 
and periconceptional supplementation with folic acid 
(the synthetic form) are effective in reducing the preva-
lence of neural tube defects (NTD) and other congenital 
malformations. An adequate folate status in women be-
fore pregnancy is a protective factor toward these pathol-
ogies. In 2009 EUROCAT published a special report 
highlighting that the majority of women in Europe were 
still not taking folic acid preconceptionally and/or were 
beginning to take it too late to prevent CA after their preg-
nancy had been confirmed. As a result, the impact of pol-
icy on the rate of NTD in the population was minimal, 
and socioeconomic inequalities widen due to differences 
in knowledge. Furthermore, the dietary intake of folates 
may not be sufficient to protect vulnerable women  [20] . 
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Many non-European countries, such as USA and Canada, 
have instituted mandatory food (flour) fortification with 
folic acid as a way forward, with a positive impact in re-
ducing NTD prevalence  [21, 22] . However, fortification 
also raises concerns about the possible ‘side effects’ of 
high folic acid intake in non-target population groups 
which might be related to increased cancer promotion. In 
2009 the scientific committee organized by EFSA (Euro-
pean Food Safety Authority) concluded that ‘There are 
currently insufficient data to allow a full quantitative risk 
assessment of folic acid and cancer or to determine 
whether there is a dose-response relationship or a thresh-
old level of folic acid intake associated with potential 
colorectal cancer risk. The current evidence does not 
show an association between high folic acid intakes and 
cancer risk, but neither do they confidently exclude a risk. 
The uncertainties in relation to cancer risk highlight the 
importance of ensuring monitoring systems are set up for 
assessment of folic acid intake and status and NTD and 
cancer incidence in countries that decide to introduce 
mandatory fortification’  [23] .
 Particular attention should be given to (i) deficiency of 
vitamins B12 and B6, since they are needed for the proper 
metabolism of folates, and (ii) zinc deficiency as a risk fac-
tor for NTD in communities from developing countries. 
In addition, pregnant women should avoid an excessive 
exposure to vitamin A associated to liver consumption 
and taking supplements containing vitamin A  [27–31] .
 A recognized example of a food contaminant highly 
relevant to the safety of the unborn child is methylmer-
cury in certain fish groups  [32–34] . The developmental 
hazards (especially urogenital malformations) from di-
etary exposure to endocrine disrupters also deserve con-
sideration (see also below ‘Field of Environmental Pollu-
tion Including the Workplace’)  [35] .
 Active smoking is a risk factor for CA  [36] . The evi-
dence regarding passive smoking is more difficult to es-
tablish but is considered to be biologically plausible  [37] .
 In the Field of Health Services 
•  To make available preconceptional care including 
genetic testing and counseling for families at risk  [42–45] ;
 •  to ensure that women with diabetes, epilepsy, and 
other chronic diseases receive preconceptional care in or-
der to minimize the risk of CA  [46, 47] ;
 •  to ensure evidence-based vaccination policies to 
guarantee women are protected against infectious diseas-
es associated with CA and avoid contraindicated vaccina-
tions during pregnancy  [48, 49] ;
 •  to include the awareness in school educational pro-
grams that CA may be caused very early in pregnancy, 
often before the pregnancy is confirmed, and hence, 
healthy practices should start preconceptionally;
 •  to include consideration of specific pregnancy-relat-
ed actions in public health action plans on all the major 
health determinants.
 Notes 
 Preconception health refers to the health of women 
and men during their reproductive years. It focuses on 
steps that women, men, and health professionals can take 
to reduce risks, promote healthy lifestyles, and increase 
readiness for pregnancy  [42–44] .
 Proposed recommendations from published research 
and recommendations from the Centers for Disease Con-
trol and Prevention (CDC)  [45] :
 (1) Individual responsibility across the life span – each 
woman, man, and couple should be encouraged to have a 
reproductive life plan. Individuals identified as having a 
family history of developmental delays, CA, or other ge-
netic disorders should be offered a referral to an appro-
priate specialist to better quantify the risk to a potential 
pregnancy.
 (2) Health professionals’ responsibility – the challenge 
for health professionals is to reach women and men with 
these interventions at the time they will be most effective 
in reducing risks. Suspected genetic disorders might re-
quire further workup prior to conception. Known or dis-
covered genetic conditions should be managed optimally 
before and after conception. As a part of primary care 
visits, provide risk assessment and educational and health 
promotion counseling to all women of childbearing age 
to reduce reproductive risk and improve pregnancy out-
comes.
 (3) Consumer awareness – increase public awareness 
of the importance of preconception health behaviors and 
preconception care services by using information and 
tools appropriate across various ages, literacy, including 
health literacy, and cultural/linguistic contexts.
 (4) Research – increase the evidence base and promote 
the use of evidence to improve preconception health.
 (5) Monitoring improvements – maximize public 
health surveillance and related research mechanisms to 
monitor preconception health.
 Pearls for practice: women should also be informed that 
preconception care can improve health outcomes for both 
mother and baby. First, ask every women of reproductive 
age whether she intends to become pregnant in the next 
year. Asking every woman about her reproductive inten-
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tions promotes the idea that pregnancies should be intend-
ed. Second, inform women that health conditions and 
medications can affect pregnancy outcomes  [45] .
 During preconception screening visits, clinicians 
should focus on issues such as folate supplementation, 
hypothyroidism management, obesity control, hepatitis 
B vaccination for at-risk women, and rubella vaccination 
among previously unvaccinated women.
 Maternal diabetes is a well-established risk factor for 
CA, but the excess risk can be almost eliminated with good 
glycaemic control. Health services must be organized to 
ensure that all women with diabetes have preconception-
al care to achieve optimal glycaemic control  [46, 47] .
 Vaccination against maternal rubella is a core element 
of any primary preventive strategy as rubella during preg-
nancy is a strong teratogen. Countries should consider 
their coverage of women, whether immigrant women are 
offered vaccination, and whether women found at a first 
pregnancy not to be immune are offered vaccinations to 
protect them in subsequent pregnancies. Other vaccina-
tions should also be considered. Vaccination during the 
first trimester should only be given where there is evi-
dence of safety or evidence of a favorable benefit-risk bal-
ance  [48, 49] .
 In the Field of Environmental Pollution Including the 
Workplace 
•  To further the implementation of EU policies on 
high-concern chemicals, to ensure both regulatory ac-
tions and risk communication towards citizens in order 
to minimize exposure to pollutants identified as terato-
gens  [50–60] ;
 •  to ensure a suitable surveillance system where envi-
ronmental risks can be identified through the integration 
of CA registers with developments in biomonitoring  [61] ;
 •  to minimize exposure of pregnant workers in their 
workplace to risk factors for CA (chemical, physical, and 
biological)  [62–69] .
 Notes 
 The ‘environment’ as used here is all the physical, chem-
ical, and biological factors external to the human host and 
all related behaviors but excluding those natural environ-
ments that cannot reasonably be modified. This definition 
excludes behavior not related to environment as well as 
behavior related to the social and cultural environment, 
genetics, and parts of the natural environment  [50] .
 In the field of the environmental causes of CA, evi-
dence is still limited and inadequate to show a causal as-
sociation; however, the biological plausibility and special 
vulnerability of the fetus supports precautionary actions 
(Communication from the European Commission on the 
precautionary principle, Brussels, 2000). In particular, re-
duction of the level of exposure to hazards acting on a 
large scale, such as air pollutants, byproducts of drinking 
water disinfection, and pesticides, should be recom-
mended  [52–56] .
 Endocrine disrupters are recognized risk factors for 
reproductive disorders during puberty and adulthood; 
however, evidence indicates that higher exposure levels 
may increase the incidence of urogenital malformations 
such as cryptorchidism and hypospadias  [57–60] .
 There is a general consensus that further elucidation 
of the links between environmental exposures and CA 
must come through linking biomarkers and CA surveil-
lance approaches  [61] .
 Pregnant women at work must be protected from ter-
atogenic exposures. The challenge is to do this in early 
pregnancy, often before the pregnancy has been con-
firmed or employers are made aware. This issue should 
be addressed in occupational health policies. Occupa-
tional exposures of concern include pesticides, any endo-
crine disrupting exposure, and organic solvents  [62–69] .
 Types of Primary Preventive Actions and Their 
Effectiveness 
 A number of types of primary preventive action can be 
identified:
 (1) Advice to future parents by health professionals 
during individual preconceptional and early pregnancy 
consultations, tailored for high- and ‘low’- (average pop-
ulation) risk couples.
 (2) Health education campaigns targeted to potential 
future parents.
 (3) EU-based and/or national regulatory actions which 
affect risk factors at source such as medicines, chemicals, 
infectious agents, foods, tobacco and alcohol, and other 
recreational drugs.
 (4) Surveillance, research, and evaluation generating 
evidence for the initiation or updating of primary preven-
tive measures. This includes also the establishment of ex-
pert committees to review evidence.
 The effectiveness of targeted actions towards the pri-
mary prevention of CA is expected to be markedly im-
proved by:
 •  An integrated primary prevention plan involving all 
relevant health professionals thus avoiding isolated and/
or uncoordinated actions/recommendations;
D
ow
nl
oa
de
d 
by
: 
Ve
rla
g 
S.
 K
AR
G
ER
 A
G
 B
AS
EL
17
2.
16
.7
.1
59
 - 
4/
11
/2
01
4 
7:
52
:5
5 
AM
 European Recommendations for Primary 
Prevention of Congenital Anomalies 
Public Health Genomics 2014;17:115–123
DOI: 10.1159/000360602
121
 •  implementation and refinement of EU food and en-
vironmental control programs providing special atten-
tion to CA risk factors;
 •  proper evaluation and integration of new scientific 
knowledge into public health actions;
 •  ensuring preconception health care in local public 
health programs  [70–74] while recognizing that many 
pregnancies are unplanned;
 •  availability of epidemiological surveillance data from 
population-based CA registers to monitor the effective-
ness of services and interventions to build a sound evi-
dence base for policy development planning and action;
 •  ensuring sustainability through national and inter-
national funding.
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